Ancient Chinese Exercise Baduanjin Cuts Blood Pressure as Well as Brisk Walking
A large clinical trial finds baduanjin, a gentle 800-year-old Chinese practice, lowers blood pressure comparably to medication and brisk walking.
Summary
Baduanjin, a traditional Chinese movement practice combining slow exercises, controlled breathing, and meditation, significantly lowered blood pressure in adults with stage 1 hypertension. A randomized clinical trial of 216 adults found that practicing baduanjin five days per week for one year reduced 24-hour systolic blood pressure by about 3 mmHg and office readings by 5 mmHg — results comparable to first-line blood pressure medications and brisk walking. Sessions last just 10–15 minutes, require no equipment, and participants maintained benefits without ongoing supervision, making this an unusually practical and sustainable lifestyle tool for blood pressure management.
Detailed Summary
High blood pressure is one of the most significant preventable drivers of heart disease globally, yet many people struggle to maintain the exercise habits doctors recommend to manage it. Baduanjin, a structured Chinese movement practice over 800 years old, may offer an accessible and sustainable solution backed now by rigorous clinical evidence.
Researchers conducted the first large multicenter randomized clinical trial examining baduanjin's effects on blood pressure, enrolling 216 adults aged 40 and older with stage 1 hypertension — systolic readings between 130–139 mmHg. Participants were randomized to baduanjin practice, brisk walking, or self-directed exercise for one year. Results were published in JACC, the flagship journal of the American College of Cardiology.
After both three months and twelve months, the baduanjin group showed reductions in 24-hour systolic blood pressure of approximately 3 mmHg and office systolic blood pressure of 5 mmHg compared to self-directed exercise. These gains are on par with some first-line antihypertensive medications and matched outcomes seen in the brisk walking group. Crucially, benefits persisted without continued monitoring or coaching.
Baduanjin consists of eight structured movements integrating aerobic activity, flexibility, isometric holds, and mindfulness. Sessions run just 10–15 minutes and require no equipment or gym access. This low-to-moderate intensity profile makes it broadly accessible, including for older adults or those with physical limitations that preclude higher-intensity exercise.
While findings are promising, the study population was limited to adults in seven Chinese communities with stage 1 hypertension, so generalizability to other populations warrants further investigation. Nonetheless, the combination of clinical-grade efficacy, minimal barriers to entry, and strong one-year adherence positions baduanjin as a genuinely scalable lifestyle intervention for cardiovascular health.
Key Findings
- Baduanjin practice 5 days/week reduced office systolic blood pressure by 5 mmHg over one year
- Blood pressure benefits appeared within 3 months and were sustained for the full 12-month study period
- Results were comparable to brisk walking and similar in magnitude to some first-line blood pressure medications
- Sessions require only 10–15 minutes with no equipment, making long-term adherence significantly easier
- Benefits persisted without ongoing supervision, addressing a major barrier to exercise-based interventions
Methodology
This is a research summary reporting on a large multicenter randomized clinical trial published in JACC, a high-impact peer-reviewed cardiology journal. The study enrolled 216 participants across seven communities with a one-year follow-up, representing strong evidence quality for a lifestyle intervention trial. The source is the American College of Cardiology, a credible and authoritative medical organization.
Study Limitations
The trial population was drawn from seven Chinese communities, which may limit generalizability to other ethnicities, health profiles, or cultural contexts. The article is a news summary and full methodology details — including blinding procedures, dropout rates, and adverse event data — should be verified in the primary JACC publication. Longer-term outcomes beyond one year and effects in stage 2 hypertension or medicated patients remain unstudied.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.